Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania

Phase 2 Completed 34 enrolled Massachusetts General Hospital Muhimbili University of Health and Allied Sciences · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II, randomized study of 120 adults age 18 or above who will prescribed 20mg daily Fluoxetine for 90 days following acute, ischemic stroke.

Timeline

Start: 2019-11-26
Primary completion: 2021-01-06
Completion: 2021-01-06

Publications

Background Vogel AC, Okeng'o K, Chiwanga F, Ismail SS, Buma D, Pothier L, Mateen FJ. MAMBO: Measuring ambulation, motor, and behavioral outcomes with post-stroke fluoxetine in Tanzania: Protocol of a phase II clinical trial. J Neurol Sci. 2020 Jan 15;408:116563. doi: 10.1016/j.jns.2019.116563. Epub 2019 Nov 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fluoxetine	Small molecule	20 mg	Oral

Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania

Summary

Timeline

Publications

Drugs

Indications